SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
前日終値
$13.66
−$1.20 · -8.08%
日中の時刻はETです。市場データは遅延する場合があります。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日中レンジ
現在 $13.66
52週レンジ
現在 $13.66
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
68
強気
リスク
61
高リスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
日中レンジ
現在 $13.66
52週レンジ
現在 $13.66
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 100万 USD | 760万 USD |
| 売上原価 | — | — | — | 10万 USD | 20万 USD |
| 粗利益 | — | — | — | 90万 USD | 740万 USD |
| 研究開発 | 1602.2万 USD | 1909.6万 USD | 2400.7万 USD | 3026.8万 USD | 2137.4万 USD |
| 販売・一般管理 | 1225.2万 USD | 1241.7万 USD | 1386.2万 USD | 1258.2万 USD | 1132万 USD |
| 営業費用 | 2827.4万 USD | 3151.3万 USD | 3786.9万 USD | 4285万 USD | 3269.4万 USD |
| 受取利息 | 141.1万 USD | 63.2万 USD | 52.5万 USD | 31.7万 USD | 6000 USD |
| 減価償却費と償却費 | — | 3151.3万 USD | 3786.9万 USD | 45.7万 USD | 127.3万 USD |
| 営業利益 | −2827.4万 USD | −3151.3万 USD | −3786.9万 USD | −4195万 USD | −2529.4万 USD |
| 純利益 | −2686.3万 USD | −3088.1万 USD | −3734万 USD | −4130.1万 USD | −2069.9万 USD |
会社概要が更新されました 2026年11月22日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$35.00
上昇余地(156.22%)この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI8630.15万0.90%96.36億 USD0.35%$140.18-2.73%
iShares Russell 2000 ETFIWM7389.39万0.10%715.37億 USD0.19%$256.61-2.88%
iShares Russell 2000 Growth ETFIWO2831.18万0.21%127.32億 USD0.24%$320.43-3.57%
Vanguard Extended Market ETFVXF2215.68万0.02%302億 USD0.05%$211.44-3.21%
Schwab U.S. Small-Cap ETFSCHA1562.09万0.08%204.47億 USD0.03%$30.51-2.83%
Vanguard Russell 2000 ETFVTWO1144.64万0.06%168億 USD0.06%$103.76-2.76%
iShares Micro-Cap ETFIWC830.35万0.77%10.88億 USD0.60%$157.87-3.19%
Vanguard Health Care ETFVHT583.94万0.02%208億 USD0.09%$326.69-0.40%
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
iShares Russell 2000 Growth ETFIWO
Vanguard Extended Market ETFVXF
Schwab U.S. Small-Cap ETFSCHA
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Vanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。